Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Have signed an informed consent document indicating that the subject understands the purpose of and procedures required for the study and are willing to participate in the study~2. Be willing/able to adhere to the prohibitions and restrictions specified in this protocol~3. Male aged 18 years and above~4. Eastern cooperative group (ECOG) performance status ≤2~5. Documented histologically confirmed adenocarcinoma of the prostate~6. Metastatic prostate cancer to the bone as documented by positive bone scan imaging~7. Patient must be eligible for chemotherapy with docetaxel~8. Patient must have evidence of castrate resistant prostate cancer as evidenced by a confirmed rising PSA (per Prostate Cancer Working Group 2 \[PCWG2\] criteria) and a castrate serum testosterone level (i.e. ≤ 50 mg/dL).~Exclusion Criteria:~1. Have known allergies, hypersensitivity, or intolerance to docetaxel or dexamethasone or their excipients~2. Prior pelvic radiation (e.g. external beam, brachytherapy, etc) that, in the opinion of the investigator, may lead to decreased bone marrow cellularity in a marrow sample obtained from a pelvic bone marrow biopsy~3. Ongoing systemic therapy (other than a GnRH agonist/antagonist) for prostate cancer including, but not limited to:~   1. CYP-17 inhibitors (e.g. ketoconazole, abiraterone)~  2. Antiandrogens (e.g. bicalutamide, nilutamide)~  3. Second generation antiandrogens (e.g. enzalutamide)~  4. Immunotherapy (e.g. sipuleucel-T, ipilimumab)~  5. Chemotherapy (e.g. docetaxel, cabazitaxel)~4. Prior radiopharmaceutical therapy (e.g. radium-223, strontium-89, samarium-153, etc) within the past year~5. Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements~6. Active infection or other medical condition that would make corticosteroids (i.e. dexamethasone) use contraindicated~7. Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg) Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment~8. Severe hepatic impairment (Child-Pugh Class C)~9. History of pituitary or adrenal dysfunction (note: the use of daily steroids does not exclude someone from participating in this study)~10. Have poorly controlled diabetes (HgB A1C ≥ 8%)~11. Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- burixafor hydrobromide (Type: ACTIVE_COMPARATOR): Four daily doses of burixafor hydrobromide alone
- G-CSF (Type: ACTIVE_COMPARATOR): G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
- Docetaxel (Type: EXPERIMENTAL): Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV.~The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).